ARTHEx Pharma 

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients


Beatriz Llamusi Troisi (See Profile)




Prototyping, preclinical



We have patented microRNA inhibitors to treat a rare disease which is an unmet medical need

Our therapeutic approach is novel as we target a new component of the disease pathogenesis

Our therapeutic target is not exclusive of this rare disease, but also has a role in others, which we could treat

This information is confidential, do not share or copy.

Other files:

Manuscrito publicado en Nat Com

Under evaluation at least till: 16th of September

If you want to have more information or you want to review the project, you have to login or register

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar